Thermo Fisher Scientific Prices Offering of Senior Notes
WALTHAM, Mass. -- December 4, 2013
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, announced today that it has priced its previously announced offering
of senior notes, consisting of:
*$900 million aggregate principal amount of 1.30% senior notes due 2017 at
an issue price of 99.941% of the principal amount,
*$900 million aggregate principal amount of 2.40% senior notes due 2019 at
an issue price of 99.796% of the principal amount,
*$1 billion aggregate principal amount of 4.15% senior notes due 2024 at an
issue price of 99.73% of the principal amount, and
*$400 million aggregate principal amount of 5.30% senior notes due 2044 at
an issue price of 99.928% of the principal amount.
The issuance of the notes is expected to close on December 11, 2013, subject
to customary closing conditions. The notes will pay interest on a semi-annual
The company plans to use the proceeds of the offering to fund a portion of its
acquisition of Life Technologies Corporation. On April 15, 2013, the company
announced its agreement to acquire Life Technologies for an aggregate purchase
price of approximately $13.6 billion.
The joint book-running managers for the offering are Barclays Capital Inc.,
J.P. Morgan Securities LLC and RBS Securities Inc.
Thermo Fisher has filed a registration statement on Form S-3 (including a
prospectus) with the Securities and Exchange Commission (the “SEC”) for this
offering. Prospective investors should read the prospectus forming a part of
that registration statement and the prospectus supplement related to the
offering and the other documents that the company has filed with the SEC for
more complete information about the company and this offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, these documents will be made available upon
request by the company or by any joint book-running manager for the offering.
Interested parties may obtain a prospectus or the related preliminary
prospectus supplement from Barclays Capital Inc. by directing a request to
Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by writing email@example.com or by
calling 1-888-603-5847; from J.P. Morgan Securities LLC by directing a request
to J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attn:
Investment Grade Syndicate Desk - 3rd Floor, or by calling 212-834-4533; or
from RBS Securities Inc. by directing a request to RBS Securities Inc., 600
Washington Boulevard, Stamford, CT 06901, Attn: Syndicate, or by calling
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy the notes, nor shall there be any offer, solicitation or
sale of the notes in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O’Brien, 781-622-1242
Investor Contact Information:
Ken Apicerno, 781-622-1294
Press spacebar to pause and continue. Press esc to stop.